Oxford Immunotec Announces Chief Financial Officer Transition
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that Richard Altieri, the Company’s Chief Financial Officer (CFO), will retire on April 30, 2019. The Company has appointed Matthew McLaughlin, currently Chief Financial Officer, GE Healthcare – U.S. and Canada, as his successor. Mr. McLaughlin will join Oxford Immunotec as CFO on April 8, 2019.
Today’s announcement concludes an extensive search process conducted by the Company. As part of the planned succession, Mr. Altieri, who has led Oxford Immunotec’s global finance organization as CFO since 2012, will remain an active member of the Company’s management team until his retirement date.
“During his seven year tenure, Rick successfully managed multiple financing rounds, including the Company's IPO, the acquisition and financial integration of three companies and, most recently, the divestiture of our U.S. laboratory services business,” said Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec. “We are grateful for his significant contributions to the continued growth of the company and wish him all the best in his retirement.”
“We are pleased to welcome Matt to the management team during this exciting time for the Company,” said Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec. “Matt’s global operating experience as well as his strong finance and accounting background will be a great asset as we continue to grow the Company”.
Mr. McLaughlin joins Oxford Immunotec with extensive experience building and leading businesses through growth strategies, operational improvements, supply chain and strategic partnerships. He has been the CFO of GE Healthcare – U.S. and Canada since December 2016. In this role, he was responsible for driving top-line growth and margin expansion across the largest segment of GE Healthcare’s $19B business. In addition to his financial responsibilities, he played a key operational role driving improvements across the supply chain and install teams to not only increase customer experience, but to also improve working capital performance. Prior to that, Mr. McLaughlin worked at GE Aviation, serving as Chief Financial Officer of Global Supply Chain from May 2014 to December 2016, Chief Financial Officer of GE Avionics from March 2012 to April 2014 and Executive - Financial Planning and Analysis from 2009 to February 2012. Before that Mr. McLaughlin worked for General Electric as a member of the corporate audit staff, holding various positions and ultimately leading global audit coverage of three GE businesses, including GE Aviation. Mr. McLaughlin earned his bachelor’s degree in Business Administration from Northeastern University.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease. The Company's T-SPOT®.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
This release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this release are forward-looking statements. This includes statements about Oxford Immunotec's anticipated plans and objectives, future performance and revenues, financial condition, prospects for sales of its products, growth, strategies, expectations and objectives of management. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements contained in this release reflect Oxford Immunotec's current expectations and are subject to risks and uncertainties. Actual results may differ materially from those projected or implied by forward-looking statements. Other factors that could adversely affect Oxford Immunotec's business and prospects are described under the "Risk Factors" section in its filings with the Securities and Exchange Commission ("SEC"). Oxford Immunotec's SEC filings are available for free by visiting the investor section of its website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.
Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. Investors should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. Oxford Immunotec does not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.
For Media and Investor Inquiries:
VP, Strategy & Investor Relations
Tel: +1 (508) 556-1377
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
ClarionDoor Adds New Head of Data and Analytics16.7.2019 11:00:00 CEST | Press release
Increasing efficiency of data-intensive processes creates deeper need for data scientists by insurers. SANTA BARBARA, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- The explosion of Big Data in the last five to ten years has hit the insurance industry hard due to the inability of legacy technology systems to effectively capture, store, integrate, and utilize unstructured data, in particular, and created an urgent need for data scientists. Forward-thinking insurance industry solution providers, like ClarionDoor, Inc. (ClarionDoor) , developer of enterprise-class, cloud-based rating, quoting, and issuance solutions for property and casualty (P&C) insurers, are adding bench strength with significant data mastery capabilities to help offset the gap for insurance company clients. Notably, ClarionDoor recently added Mark Heslop to the leadership team as the company’s new Head of Data and Analytics. “Mark is an important addition to our team,” said Michael DeGusta, CEO of ClarionDoor. “He will be
Epistem licence Hubrecht Organoid Technology to expand pre-clinical toxicology service portfolio16.7.2019 10:52:00 CEST | Press release
MANCHESTER, United Kingdom, July 16, 2019 (GLOBE NEWSWIRE) -- Epistem Limited, the UK based pre-clinical and clinical research services company announces the expansion of its in vitro model portfolio by the completion of an agreement with Hubrecht Organoid Technology (HUB) to enable the delivery of an increased range of multi species organoid models. Services are focused on the identification of off target or off tissue intestinal toxicities associated with various therapeutics. Specifically, Epistem aims to help customers define whether there are reasons to suspect that there may be human toxicity issues. This will allow better prioritisation of lead compounds, with customers able to make early decisions on whether to abandon, identify alternatives, or develop mitigation strategies for any drugs with human toxicity. Organoids are adult stem cell patient or animal derived structures. Organoids are genetically stable and maintain epithelial functionality in the laboratory. The expanding
Bombardier’s Multi-Award-Winning Global 7500 Jet Reaches New Heights in the Heart of the Swiss Alps15.7.2019 19:00:00 CEST | Press release
Global 7500 aircraft is the most spacious purpose-built business jet to operate out of Gstaad’s Saanen airport in Switzerland, where it was on display earlier this month before flying to Dubai, performing another exceptional long-range mission Mission highlights the Global family’s advanced wing design, which enables them to access challenging airfields with short runways in hot temperatures and/or high altitude locations, giving passengers direct access to the heart of the Swiss Alps all year round The Aviation Week Grand Laureate Global 7500 aircraft, also recently recognized as Business Jet of the Year in Robb Report’s Best of the Best 2019, offers Bombardier’s signature smooth ride and a spaciousness that is unique among business jets Bombardier’s Challenger 350 aircraft, also recognized as the Best of the Best Super Mid-size Aircraft by Robb Report, joined the Global 7500 jet on display in Gstaad and achieved a speed record, reaching Malaga in 2 hours and 4 minutes MONTREAL, July
Brookfield Asset Management 2019 Second Quarter Results Conference Call and Webcast15.7.2019 18:27:00 CEST | Press release
Date: Thursday, August 8, 2019 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, NEWS, July 15, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management (NYSE:BAM)(TSX:BAM.A)(EURONEXT AMSTERDAM:BAMA): Second Quarter Conference Call You are invited to participate in Brookfield Asset Management’s 2019 Second Quarter Conference Call & Webcast on Thursday, August 8, 2019 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on August 8th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com “News – Press Releases.” The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-866-688-9425 toll free in North America, or for overseas calls please dial 1-409-216-0815 (Conference ID: 8258617) at approximately 10:50 a.m. The Conference Call will also b
Virtusa Achieves AWS Life Sciences Competency Status15.7.2019 16:01:00 CEST | Press release
Virtusa joins a group of AWS Partner Network members helping Life Sciences providers to deliver superior patient outcomes SOUTHBOROUGH, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Virtusa Corporation (NASDAQ GS: VRTU), a global provider of digital strategy, digital engineering, and IT outsourcing services that accelerates business outcomes for its clients, announced today that it has achieved Amazon Web Services (AWS) Life Sciences Competency status. This designation recognizes Virtusa for providing deep expertise in building Life Sciences solutions on AWS to help customers conduct drug discovery, manage clinical trials, engage in manufacturing and distribution activities, conduct research and development of novel genetic-based treatments and companion diagnostics. Achieving the AWS Life Sciences Competency differentiates Virtusa as an AWS Partner Network (APN) member that has demonstrated relevant technical proficiency and proven customer success, delivering solutions seamlessly on AWS.
LGC Capital, Ltd., announces Trichomed received its cultivation license from Health Canada for its new cannabis facility in Brownsburg, Quebec15.7.2019 15:28:00 CEST | Press release
MONTREAL, July 15, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSX-V: LG / OTCQB: LGGCF) LGC Capital Ltd. (“LGC” or the “Company”), announces that Health Canada, on July 12th, awarded Trichomed Corporation (Trichomed), its long awaited license to cultivate cannabis seeds and plants at its newly constructed facility in Brownsburg, Quebec. As per the terms of its agreement with Trichomed, LGC is, now entitled to convert the first ranking secured loan it provided to Trichomed in December 2017 into a 49% direct equity interest, and a five percent (5%) royalty of Trichomed’s net sales of cannabis and cannabis-related prodcuts which covers actual sales less any arm’s length third-party discounts, merchandise returns and rebates. In addition as per the agreement, LGC is entitled to representation on Trichomed’s board. For further information, please contact: John McMullen, President Tel: (416) 803-0698 firstname.lastname@example.org Mark Shinners, Chief Financial Officer Tel: +44 7827 960971 mark@lgc-ca